Frontlight ResearchEarly access
Lung cancer trials in South Korea
170 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Seoul
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 2Taking peopleA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Cheongju-si, Daegu, Goyang-si, Seoul, Suwon, Wŏnju
- Age
- 18 years and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - Phase 1/2Taking peopleA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Where
- Seoul
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07227025 - Phase 2Taking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Cheongju-si, Daegu, Incheon, Seoul, Suwon
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - Phase 2Taking peopleA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Where
- Buk Gu, Busan, Seoul
- Age
- 18 years and over
- People
- 68 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07586202 - Phase 2/3Taking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 1,580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Hwasun, Incheon, Seoul, Suwon
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - Phase 3Taking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Goyang, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - No phaseTaking peopleDevelopment and Utilization of an Integrated Clinical Genomic Database
- Where
- Seoul
- People
- 118,750
- Run by
- Samsung Medical Center
See details and how to joinNCT07911267 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Busan, Cheongju-si, Daegu, Goyang-si, Junggu, Seoul, Suwon
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 1/2Taking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Cheongju-si, Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - Phase 1/2CompletedKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00 - No phaseCompletedKEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Where
- Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 1,065 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165798 - Phase 3Taking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - Phase 3Taking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Bupyeong-gu, Busan, Daejeon, Deagu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - Phase 1Taking peopleA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 404 worldwide
- Run by
- Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00 - Phase 3Taking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Changwon, Incheon, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Gyeonggi-do, Seoul, Songpa-gu
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Goyang-si, Seoul
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - Phase 1/2Taking peopleA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Seongbuk-Gu, Seoul
- Age
- 18 years and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Busan, Cheongju-si, Namdong-gu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 2Taking peopleA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Where
- Cheongju-si, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00